The Online Investor
Diagnostics M&A image Diagnostics M&A » By The Online Investor Staff, updated Mon., Feb. 17, 5:37 PM Recent mergers and acquisitions in the Diagnostics M&A category.

Slide #49. Catamaran Corp. RESTAT

Acquirer: Catamaran Corp. (CTRX)
Acquiree: RESTAT
Details: Catamaran Corp. (NASDAQ: CTRX, TSX: CCT), a leading provider of pharmacy benefit management (PBM) services and technology, announced today the completion, effective as of October 1, 2013, of its previously disclosed acquisition of RESTAT, LLC ("RESTAT"), for a purchase price of $409.5 million in cash, subject to certain customary post-closing adjustments. The purchase price was funded from Catamaran's existing cash balance and $350 million in borrowings under its revolving credit facility.

Catamaran is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. Co.'s PBM services are marketed under the Catamaran PBM brand and include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, Medicare Part D services, benefit design consultation, and reporting and information analysis. Co.'s HCIT solutions include RxClaim® on-line transaction processing system, RxMax® rebate management system, RxTrack® data warehouse and analysis system, Zynchros suite of formulary management tools, and other software products.

Open the CTRX Page at The Online Investor »

Company Name: 
Catamaran Corp
Website: 
www.catamaranrx.com
Sector: 
Diagnostics
 

Open the CTRX Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Hold (2.39 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Diagnostics M&A - Slide 49 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.